Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144963 · ClinicalTrials.gov registry record · Phase 1
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00144963 is a Phase 1 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 36 participants.
The verdict
NCT00144963, a Phase 1 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Interventions
- DRUG Dexamethasone
- DRUG Vincristine Sulfate Liposomes Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-07 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144963
The ClinicalTrials.gov registry entry for NCT00144963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00144963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144963 about?
NCT00144963 is a clinical study titled "Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT00144963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2002-07. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00144963?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine Sulfate Liposomes Injection (DRUG).
Who is sponsoring clinical trial NCT00144963?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.